Volume 96, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



() is the main causative species of tegumentary leishmaniasis in Brazil. In this study, we evaluated the susceptibility of 16 clinical isolates of () from different regions of Brazil to miltefosine in vitro. Half-maximal inhibitory concentrations of miltefosine varied from 22.9 to 144.2 μM against promastigotes and from 0.3 to 4.2 μM against intracellular amastigotes. No significant differences were found between isolates of different geographical origins. A clear correlation between the EC against promastigotes and amastigotes within each isolate was found. These findings contribute to the evaluation of miltefosine's potential and limitations for the treatment of tegumentary leishmaniasis in Brazil.


Article metrics loading...

Loading full text...

Full text loading...



  1. Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, , 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.[Crossref]
  2. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, , 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 17391746.[Crossref]
  3. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, , 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350356.[Crossref]
  4. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, , 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 12661272.[Crossref]
  5. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S, , 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255260.[Crossref]
  6. Oliveira MA, Pires A da S, de Bastos RP, Lima GM, Pinto SA, Pereira LI, Pereira AJ, Abrahamsohn IA, Dorta ML, Ribeiro-Dias F, , 2010. Leishmania spp. parasite isolation through inoculation of patient biopsy macerates in interferon gamma knockout mice. Rev Inst Med Trop Sao Paulo 52: 8388.[Crossref]
  7. Cupolillo E, Grimaldi G, Jr Momen H, Beverley SM, , 1995. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania . Mol Biochem Parasitol 73: 145155.[Crossref]
  8. Montalvo AM, Fraga J, Maes I, Dujardin JC, van der Auwera G, , 2012. Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification. Eur J Clin Microbiol Infect Dis 31: 14531461.[Crossref]
  9. Zauli-Nascimento RC, Miguel DC, Yokoyama-Yasunaka JK, Pereira LI, Pelli de Oliveira MA, Ribeiro-Dias F, Dorta ML, Uliana SR, , 2010. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Trop Med Int Health 15: 6876.
  10. Kumar D, Kulshrestha A, Singh R, Salotra P, , 2009. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53: 835838.[Crossref]
  11. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, , 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272275.
  12. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P, , 2012. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 6: e1657.[Crossref]
  13. Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S, , 2012. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis—status of newly introduced drugs. Am J Trop Med Hyg 87: 655657.[Crossref]
  14. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S, , 2013. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. Am J Trop Med Hyg 89: 750754.[Crossref]
  15. Obonaga R, Fernandez OL, Valderrama L, Rubiano LC, Castro M del M, Barrera MC, Gomez MA, Gore Saravia N, , 2014. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother 58: 144152.[Crossref]
  16. Hendrickx S, Eberhardt E, Mondelaers A, Rijal S, Bhattarai NR, Dujardin JC, Delputte P, Cos P, Maes L, , 2015. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome. J Antimicrob Chemother 70: 30233026.[Crossref]
  17. Soto J, Berman J, , 2006. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100 (Suppl 1): S34S40.[Crossref]
  18. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodriguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Perez M, Nicholls RS, Gore Saravia N, , 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205: 684692.[Crossref]

Data & Media loading...

  • Received : 15 Oct 2016
  • Accepted : 02 Dec 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error